Loading
Nanoparticle-based Drug Delivery / Virus-based Gene Therapy Research / RNA Interference and Gene Delivery · Journal article
Journal of Biomaterials Science Polymer Edition · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review surveying recent advances in protein-based nanocarriers for non-viral gene delivery to cancer cells. The source presents conceptual and preclinical rationale for the approach but does not report original clinical trial data, outcomes, or comparative efficacy evidence.
Journal article.
Protein-based nanocarriers offer intrinsic biocompatibility, biodegradability, and structural versatility for encapsulation and controlled release of nucleic acids. Gene therapy applications have expanded from monogenic disorders to inherited and acquired diseases, including cancer. Recombinant peptides used in gene therapy face challenges including high toxicity, instability, poor bioavailability, and costly production.
Recombinant peptides used in gene therapy face challenges including high toxicity, instability, poor bioavailability, and costly production.
The source did not state who this applies to in practice.
This is a narrative review article surveying the landscape of protein-based nanocarriers for gene delivery; it raises questions and synthesizes existing work rather than presenting original empirical findings or clinical outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Gene therapy has emerged as one of the most promising approaches in both medical and biotechnological fields due to its capacity to modify, optimize, and regulate target DNA sequences. Recent advancements integrating gene therapy with nanotechnology, particularly through nano-carrier systems, have enabled precise delivery of therapeutic nucleic acids with controlled release at specific pathological sites [1]. Initially focused on monogenic disorders, gene therapy applications have now expanded to a broad spectrum of inherited and acquired diseases [2]. Protein-based nanocarriers have attracted considerable attention as next-generation non-viral vectors due to their intrinsic biocompatibility, biodegradability, and structural versatility [3]. Their ability to encapsulate nucleic acids, support controlled release, and enable targeted delivery makes them attractive candidates for cancer gene therapy. These unique characteristics position protein-based nanocarriers as a cell-friendly and effective strategy for improving the safety and efficiency of gene delivery systems [4]. Consequently, they represent a promising strategy for improving the safety and efficacy of cancer gene therapy. The development of safe, efficient, and biocompatible vectors remains a critical determinant of therapeutic success. Recombinant peptides, despite their therapeutic potential, face challenges such as high toxicity, instability, poor bioavailability, and costly production, which gene therapy strategies aim to overcome [5]. Techniques including gene knockdown, mutation correction, and gene insertion are central to modern gene therapy approaches. This article reviews the recent progress and challenges associated with nano-based non-viral vectors designed for targeted delivery of DNA into cancerous cells.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.